Show channels:
All channels
Bladder cancer
Brain and spinal
Breast cancer
Cervical
Colon & rectal
Dermatological
General Information
Gynecological
Head and Neck
Kidney/adrenal
Liver
Lung
Lymphoma
Multiple Myeloma
Myelodysplastic syndromes
Myeloproliferative disorders
Pancreas
Pediatric
Prostate
Sarcoma
Stomach
Testicular
Thyroid
Upper aerodigestive
Found 15757 articles
CircZBTB44 promotes renal carcinoma progression by stabilizing HK3 mRNA structure
HK3 exerted oncogenic effects on RCC cell malignant behaviors and tumor growth.
»
04/27/23
TP53 somatic mutations in Asian breast cancer are associated with subtype-specific effects
TP53 somatic mutations associated with higher HR deficiency scores.
»
04/26/23
Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre
Overall grade 3 or worse toxicity similar in DPYD variant carriers.
»
04/26/23
MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat
MYC expression elevated following acquisition of platinum resistance.
»
04/26/23
Aspirin or statin use in relation to survival after surgery for esophageal cancer: a population-based cohort study
Analyses stratified by subgroups of age, sex, tumor stage, and tumor histology did not reveal any associations between aspirin or statin use.
»
04/25/23
Carbonic anhydrases reduce the acidity of the tumor microenvironment, promote immune infiltration, decelerate tumor growth, and improve survival in ErbB2/HER2-enriched breast cancer
Patient survival benefits associated with high extracellular carbonic anhydrase expression in HER2-enriched breast.
»
04/25/23
High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma
Identified five classes of agents with potential pharmacological efficacy.
»
04/25/23
Hypoxia disrupt tight junctions and promote metastasis of oral squamous cell carcinoma via loss of par3
HIF-1α overexpressed in patients with OSCC.
»
04/24/23
PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients.
Feasibility and potential benefit of strategy in patients with oligometastatic progression under PARPi.
»
10/26/22
Relationship Between Baseline Prostate-specific Antigen on Cancer Detection and Prostate Cancer Death: Long-term Follow-up from the European Randomized Study of Screening for Prostate Cancer.
Baseline PSA <1.0 ng/ml for men aged 55-69 yr strong indicator to delay or stop further screening.
»
10/18/22
< Prev
Next >